Your browser doesn't support javascript.
loading
Differences in imeglimin response in subgroups of patients with type 2 diabetes stratified by data-driven cluster analysis: A post-hoc analysis of imeglimin clinical trial data.
Hagi, Katsuhiko; Kochi, Kenji; Watada, Hirotaka; Kaku, Kohei; Ueki, Kohjiro.
Afiliación
  • Hagi K; Medical Science, Sumitomo Pharma Co., Ltd, Tokyo, Japan.
  • Kochi K; Data Science, Sumitomo Pharma Co., Ltd, Tokyo, Japan.
  • Watada H; Department of Metabolism and Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Kaku K; Department of Medicine, Kawasaki Medical School, Okayama, Japan.
  • Ueki K; Department of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine, Tokyo, Japan.
Diabetes Obes Metab ; 26(9): 3732-3742, 2024 Sep.
Article en En | MEDLINE | ID: mdl-38924336
ABSTRACT

AIM:

To explore differences in imeglimin response among type 2 diabetes (T2D) patient clusters using data-driven cluster analysis.

METHODS:

Data-driven cluster analysis (non-hierarchical k-means clustering) was performed on randomized, double-blind, imeglimin monotherapy and adjunctive (to insulin) therapy trials based on four baseline variables (1) disease duration; (2) body mass index (BMI); (3) HbA1c; and (4a) homeostatic model assessment of ß-cell function (HOMA-ß) (monotherapy trials) or (4b) insulin total daily dose (adjunctive trial).

RESULTS:

Four clusters were identified with distinct clinical characteristics in both monotherapy (1-4) and adjunctive therapy (I-IV) trials; clusters 1 and I had lower values across all four indices versus the overall population, clusters 2 and II had a longer diabetes duration, cluster 3 had higher baseline BMI and HOMA-ß, and cluster III had higher baseline BMI and insulin total daily dose, while clusters 4 and IV had higher baseline HbA1c. Between-group differences in HbA1c change (95% confidence interval) and effect size (ES) at week 24 varied considerably by cluster (cluster 1 -0.82 [-1.00, -0.63], ES = 1.47; cluster 2 -0.64 [-0.89, -0.39], ES = 1.18; cluster 3 -0.86 [-1.38, -0.33], ES = 0.84; cluster 4 -1.27 [-1.73, -0.82], ES = 1.44). For imeglimin adjunctive therapy, HbA1c improvements were significant versus placebo at week 16, excluding cluster III (cluster I -0.63 [-0.95, -0.31], ES = 0.88; cluster II -0.66 [-1.02, -0.30], ES = 1.13; cluster III -0.31 [-0.73, 0.11], ES = 0.46; cluster IV -0.82 [-1.29, -0.35], ES = 0.99).

CONCLUSIONS:

Differences in imeglimin response were observed among T2D patient clusters. Patient stratification may help with selection of those most probable to respond to imeglimin.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Hemoglobina Glucada / Diabetes Mellitus Tipo 2 / Hipoglucemiantes / Insulina Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Diabetes Obes Metab Asunto de la revista: ENDOCRINOLOGIA / METABOLISMO Año: 2024 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Hemoglobina Glucada / Diabetes Mellitus Tipo 2 / Hipoglucemiantes / Insulina Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Diabetes Obes Metab Asunto de la revista: ENDOCRINOLOGIA / METABOLISMO Año: 2024 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido